For instance, IL-23p19 inhibitors such as risankizumab, guselkumab, tildrakizumab, and mirikizumab demonstrate a favorable risk-benefit ratio in patients with moderate-to-severe psoriasis (75) and are more effective than ustekinumab (which is widely approved in multiple countries for CD treatment) (76, 82, 83). Here, IL23A is linked to psoriasis.